Skip to content


A-Alpha Bio

IT Software

CoMotion Labs - Fluke Hall



A-ALPHA BIO has developed AlphaSeq, a breakthrough approach for quantitatively profiling the effect of a small molecule drug or biologic on whole PPI networks. AlphaSeq is a unique cell-based assay that combines the throughput of a genetically encoded protein characterization platform with the accuracy of a biophysical technique. This approach enables pharmaceutical companies and other research groups to efficiently characterize their drug candidates for efficacy and specificity and better predict how each will perform in the clinic. We are currently looking for academic and industry partners to pilot AlphaSeq for ongoing preclinical drug development projects.

Team Members

David Younger

Co-Founder & CEO

Randolph Lopez

Co-Founder & CTO